GlassScriptPhysician profile
Janel Brink
NPI 1487067633
$1,876.49
in general payments reported to CMS, 2019-2025
30 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $21.14 · 2022: $373 · 2023: $363 · 2024: $536 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $259.54 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Hologic Sales and Service, LLC | $223.47 | 2022-2025 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Astellas Pharma US INC | $188.21 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $181.38 | 2019-2025 | |
| Abbvie INC. | $150.46 | 2019-2024 | Lo Loestrin Fe, Liletta |
| Organon LLC | $89.86 | 2023-2025 | Nexplanon |
| Sage Therapeutics, LLC | $78.31 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $75.53 | 2022-2025 | |
| Exeltis, USA INC. | $65.71 | 2022-2025 | Slynd |
| Pfizer INC. | $61.21 | 2023 | |
| Daiichi Sankyo INC. | $57.34 | 2023-2024 | Injectafer |
| Medtronic, INC. | $47.85 | 2024 | Ligasure, Abre |
| Sanofi Pasteur INC. | $47.47 | 2019 | |
| Amag Pharmaceuticals, INC. | $36.44 | 2019 | |
| Baxter Healthcare | $32.78 | 2024 | Perclot |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $31.20 | 2025 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $25.63 | 2019 | |
| Sumitomo Pharma America, INC. | $21.96 | 2023 | Myfembree |
| Medicem INC. | $21.87 | 2022 | |
| Mission Pharmacal Company | $21.85 | 2019 | |
| Bausch Health US, LLC | $21.14 | 2020 | |
| Becton, Dickinson and Company | $18.33 | 2024 | Bd Onclarity |
| Meditrina | $17.85 | 2025 | |
| Supernus Pharmaceuticals, INC. | $16.95 | 2025 | Qelbree |
| Lilly USA, LLC | $15.41 | 2025 | Zepbound |
| Evofem Biosciences, INC. | $14.27 | 2022 | |
| Ibsa Pharma INC. | $14.11 | 2022 | |
| Vertical Pharmaceuticals, LLC | $13.65 | 2019 | |
| Minerva Surgical, INC | $13.52 | 2023 | |
| Merck Sharp & Dohme LLC | $13.19 | 2023 | Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janel Brink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.